Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Patients With Lysosomal Acid Lipase Deficiency
Published : 2011-06-06 - Updated : 2016-06-11
Author : Synageva BioPharma Corp.
Synopsis: Open label dose escalation study in adult patients with liver dysfunction due to Lysosomal Acid Lipase (LAL) Deficiency.
Synageva BioPharma Corp. has initiated a clinical study to evaluate the safety, tolerability, and pharmacokinetics of SBC-102 as an enzyme replacement therapy for cholesteryl ester storage disease (CESD).
This is the first clinical study of SBC-102 for the treatment of LAL Deficiency.
It is an open label dose escalation study in adult patients with liver dysfunction due to Lysosomal Acid Lipase (LAL) Deficiency and will examine three doses of SBC-102.
The targeted number for this study is 9 evaluable subjects.
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Cholesterol Ester Storage Disease(CESD)|
Lysosomal Acid Lipase Deficiency
|Drug: SBC-102||Phase I|
An Open Label Multi-center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Patients With Liver Dysfunction Due to Lysosomal Acid Lipase Deficiency
Further study details as provided by Synageva BioPharma Corp.:
Primary Outcome Measures:
Safety and Tolerability of SBC-102 [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
The safety and tolerability of weekly infusions of SBC-102 will be assessed by routine monitoring of patients for adverse events (AEs) and monitoring changes from baseline in physical examination findings, vital signs, clinical laboratory evaluations, immunogenicity tests and concomitant therapies.
Secondary Outcome Measures:
Pharmacokinetics of SBC-102 [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
Characterize the pharmacokinetics of SBC-102 delivered by IV infusion after single and multiple doses.
|Study Start Date:||February 2011|
|Estimated Study Completion Date:||May 2011|
|Estimated Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
|Cohort 1: Experimental|
Cohort 1: Weekly IV infusions of Dose A of SBC-102
Intervention: Drug: SBC-102
Weekly IV infusions Dose A of SBC-102
|Cohort 2: Experimental|
Cohort 2: Weekly IV infusions of Dose B of SBC-102
Intervention: Drug: SBC-102
Weekly IV infusions Dose B of SBC-102
|Cohort 3: Experimental|
Cohort 3: Weekly IV infusions of Dose C of SBC-102
Intervention: Drug: SBC-102
Weekly IV infusions Dose C of SBC-102
Cholesteryl Ester Storage Disease (CESD) is the late onset phenotype for Lysosomal Acid Lipase (LAL) Deficiency, a Lysosomal Storage Disorder, which also has an early onset phenotype known as Wolman Disease that primarily affects infants. CESD can present in childhood but often goes unrecognized until adulthood when the underlying pathology is advanced. Many of the signs and symptoms are common to patients with other liver conditions.
CESD is an autosomal recessive genetic condition and is characterized by hepatomegaly, persistently abnormal liver function tests (LFTs) and type II hyperlipidemia. Splenomegaly and evidence of mild hypersplenism may affect some patients. Untreated, CESD may lead to fibrosis, cirrhosis, liver failure and death.
Disease Risk In Families:
- 25 per million incidence
- Autosomal recessive disorder, LAL deficiency is carried on chromosome 10
- Parents with an affected son or daughter have a 1 in 4 chance of having another affected child
|Ages Eligible for Study:||18 Years to 65 Years|
|Genders Eligible for Study:||Both|
|Accepts Healthy Volunteers:||No|
- Male or female patients 18 and 65 years of age
- Documented decreased LAL activity
- Evidence of liver involvement
- Clinically significant concurrent disease, serious inter-current illness, concomitant medications or other extenuating circumstances
- Clinically significant abnormal values on laboratory screening tests, other than liver function or lipid panel tests
- AST and/or ALT persistently elevated > 3xULN at screening
- Previous hemopoietic bone marrow or liver transplant
- Current history of alcohol abuse
Contacts and Locations:
Please refer to this study by its ClinicalTrials.gov identifier: NCT01307098
|Contact: Jennifer Burgfirstname.lastname@example.org|
|United States, California|
|Palo Alto, California, United States, 94304|
|Contact: Katherine Connors, MPH 650-736-8166 email@example.com|
|Principal Investigator: Gregory Enns, MD|
|United States, New York|
|Mount Sinai School of Medicine||Recruiting|
|New York, New York, United States, 10029|
|Contact: Louise Bier, MS 212-241-0915 firstname.lastname@example.org|
|Principal Investigator: Manisha Balwani, MD, MS|
|United States, Pennsylvania|
|Children's Hospital of Pittsburgh of UPMC||Recruiting|
|Pittsburgh, Pennsylvania, United States, 15224|
|Contact: Michele Graham 412-692-3476 Michele.Graham@chp.edu|
|Principal Investigator: David Finegold, MD|
Prof. Wraith, MD
Wellcome Trust Clinical Research Facilities
Manchester Royal Infirmary
Dr Patrick Deegan,
Addenbrooke's Lysosomal Disorders Unit
Cambridge University Hospitals,
1st Faculty of Medicine Charles University
Department of Paediatrics
Ke Karlovu 2
Dr. Vassili Valayannopoulos
Hopital Necker-Enfants Malades
Inherited Metabolic Disorders
149, Rue des Sevres
Sponsors and Collaborators:
Synageva BioPharma Corp.
|Responsible Party:||Synageva BioPharma Corp. (Mark Hites)|
|ClinicalTrials.gov Identifier:||NCT01307098 History of Changes|
|Other Study ID Numbers:||LAL-CL01|
|Study First Received:||March 1, 2011|
|Last Updated:||May 17, 2011|
|Health Authority:||United States: Food and Drug Administration; United Kingdom: Medicines and Healthcare Products Regulatory Agency|
You're reading Disabled World. See our homepage for informative disability news, reviews, sports, stories and how-tos. You can also connect with us on social media such as Twitter and Facebook or learn more about Disabled World on our about us page.
Disclaimer: Disabled World provides general information only. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information. Please report outdated or inaccurate information to us.
Cite Page: Journal: Disabled World. Language: English (U.S.). Author: Synageva BioPharma Corp.. Electronic Publication Date: 2011-06-06 - Revised: 2016-06-11. Title: Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Patients With Lysosomal Acid Lipase Deficiency, Source: <a href=https://www.disabled-world.com/medical/clinical-trials/lysosomal-acid-lipase-deficiency.php>Safety, Tolerability and Pharmacokinetics of SBC-102 in Adult Patients With Lysosomal Acid Lipase Deficiency</a>. Retrieved 2021-06-19, from https://www.disabled-world.com/medical/clinical-trials/lysosomal-acid-lipase-deficiency.php - Reference: DW#340-7866.